|
 |
| International Symposium on Airway Diseases: Etiology to Clinic |
| 24th & 25th Feb 2012, Gurgaon, INDIA |
|
Organized by Daiichi Sankyo India Pharma Pvt. Ltd. (DSIN)
and
Ranbaxy Laboratories Ltd. |
|
Daiichi Sankyo Life Science Research Centre in India (RCI) is a research based drug discovery unit. RCI is a part of Daiichi Sankyo India Pharma Private Limited (DSIN), which is a wholly owned subsidiary of Daiichi Sankyo Co. Ltd., Japan. RCI is committed to find new drugs for obstructive diseases of airway like Asthma, COPD and Fibrosis. These diseases have high prevalence and high unmet needs. The symposium is an attempt to showcase RCI management's commitment for research on diseases of respiratory system.
Ranbaxy Laboratories Limited is a research based global pharmaceutical company, headquartered in India. A member of Daiichi Sankyo Group, Ranbaxy develops, produces and markets high quality, affordable generic medicines in over a 125 countries. Ranbaxy and Daiichi Sankyo are successfully working together in advancing a unique Hybrid Business Model that comprehensively addresses the requirements of Doctors and Patients, while improving the availabilty and accessibility to high quality affordable medication.
Ths symposium is aimed at bringing scientists and administrators from academia, industry and government under one roof, to share current understanding on the subject of Airway Diseases and finding support for drug discovery research in this therapeutic segment. |
|
| Topics |
 |
 |
Epidemiology/Etiology of – COPD, Asthma and Fibrosis |
|
Key Unmet Needs |
|
Drug Discovery - recent developments and therapeutic targets |
|
|
|
